Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status
Background: Current decision-making for the treatment of breast cancer liver metastases (BCLM) using ablation lacks strong evidence, especially for patients combined with extrahepatic metastases. Purpose: To assess whether ablation plus systemic therapy (AS) improves survival outcomes in patients wi...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977625000050 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856881463984128 |
|---|---|
| author | Xuxiazi Zou Hong-Liang Zou Xuan Luo Xu-Wei Chen Wei-Ling Huang Chao Zhang Ge Ren Jin-Hua Huang Xue Han Yi-Quan Jiang |
| author_facet | Xuxiazi Zou Hong-Liang Zou Xuan Luo Xu-Wei Chen Wei-Ling Huang Chao Zhang Ge Ren Jin-Hua Huang Xue Han Yi-Quan Jiang |
| author_sort | Xuxiazi Zou |
| collection | DOAJ |
| description | Background: Current decision-making for the treatment of breast cancer liver metastases (BCLM) using ablation lacks strong evidence, especially for patients combined with extrahepatic metastases. Purpose: To assess whether ablation plus systemic therapy (AS) improves survival outcomes in patients with BCLM compared to systemic therapy alone. Materials and methods: This retrospective study analyzed patients with BCLM who received either AS or systemic therapy alone. Propensity score matching (PSM) and survival analysis were performed, taking into account factors like the characteristics of primary breast cancer, liver metastases and systemic therapies received. Results: The study included 1021 female patients, with a median follow-up of 39.6 months. Of these patients, 132 underwent AS and 836 received systemic therapy alone. After PSM, among patients with BCLM (≤3 tumors, each ≤3 cm), the median overall survival (OS) for those treated with AS or systemic therapy alone was 65.5 and 40.4 months, respectively (HR = 0.48, p = .003); in the subset of patients with extrahepatic metastases, the median OS for those treated with AS and systemic therapy alone was 46.4 and 40.8 months, respectively (HR = 0.58, p = .047). Among patients with >3 cm or >3 lesions, the median OS for those treated with AS or systemic therapy alone was 45.2 and 29 months, respectively (HR = 0.67, p = .084). Conclusions: Among patients with BCLM (≤3 tumors, each ≤3 cm), AS provide longer survival compared to systemic therapy alone, even with extrahepatic metastases. For patients with larger or more numerous metastases (>3 cm or >3 lesions), AS may provide survival benefit, but further validation is needed. |
| format | Article |
| id | doaj-art-1395c446fabf455e97d3592fcf46d2ef |
| institution | Kabale University |
| issn | 1532-3080 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj-art-1395c446fabf455e97d3592fcf46d2ef2025-02-12T05:30:39ZengElsevierBreast1532-30802025-02-0179103876Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases statusXuxiazi Zou0Hong-Liang Zou1Xuan Luo2Xu-Wei Chen3Wei-Ling Huang4Chao Zhang5Ge Ren6Jin-Hua Huang7Xue Han8Yi-Quan Jiang9Department of Breast Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR ChinaDepartment of Minimally Invasive Interventional Therapy, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, PR ChinaDepartment of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 33, Yingfeng Road, Haizhu District, Guangzhou, 510289, Guangdong, PR ChinaDepartment of Breast Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR ChinaDepartment of Breast Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR ChinaDepartment of Breast Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR ChinaDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong KongDepartment of Minimally Invasive Interventional Therapy, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR ChinaDepartment of Minimally Invasive Interventional Therapy, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China; Corresponding author. Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, PR China.Department of Minimally Invasive Interventional Therapy, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China; Corresponding author. Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, PR China.Background: Current decision-making for the treatment of breast cancer liver metastases (BCLM) using ablation lacks strong evidence, especially for patients combined with extrahepatic metastases. Purpose: To assess whether ablation plus systemic therapy (AS) improves survival outcomes in patients with BCLM compared to systemic therapy alone. Materials and methods: This retrospective study analyzed patients with BCLM who received either AS or systemic therapy alone. Propensity score matching (PSM) and survival analysis were performed, taking into account factors like the characteristics of primary breast cancer, liver metastases and systemic therapies received. Results: The study included 1021 female patients, with a median follow-up of 39.6 months. Of these patients, 132 underwent AS and 836 received systemic therapy alone. After PSM, among patients with BCLM (≤3 tumors, each ≤3 cm), the median overall survival (OS) for those treated with AS or systemic therapy alone was 65.5 and 40.4 months, respectively (HR = 0.48, p = .003); in the subset of patients with extrahepatic metastases, the median OS for those treated with AS and systemic therapy alone was 46.4 and 40.8 months, respectively (HR = 0.58, p = .047). Among patients with >3 cm or >3 lesions, the median OS for those treated with AS or systemic therapy alone was 45.2 and 29 months, respectively (HR = 0.67, p = .084). Conclusions: Among patients with BCLM (≤3 tumors, each ≤3 cm), AS provide longer survival compared to systemic therapy alone, even with extrahepatic metastases. For patients with larger or more numerous metastases (>3 cm or >3 lesions), AS may provide survival benefit, but further validation is needed.http://www.sciencedirect.com/science/article/pii/S0960977625000050AblationBreast cancer liver metastasesLiver resectionSystemic therapy |
| spellingShingle | Xuxiazi Zou Hong-Liang Zou Xuan Luo Xu-Wei Chen Wei-Ling Huang Chao Zhang Ge Ren Jin-Hua Huang Xue Han Yi-Quan Jiang Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status Breast Ablation Breast cancer liver metastases Liver resection Systemic therapy |
| title | Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status |
| title_full | Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status |
| title_fullStr | Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status |
| title_full_unstemmed | Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status |
| title_short | Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status |
| title_sort | retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases stratified by extrahepatic metastases status |
| topic | Ablation Breast cancer liver metastases Liver resection Systemic therapy |
| url | http://www.sciencedirect.com/science/article/pii/S0960977625000050 |
| work_keys_str_mv | AT xuxiazizou retrospectivecomparativesurvivalanalysisofablationplussystemictherapyversussystemictherapyaloneforbreastcancerlivermetastasesstratifiedbyextrahepaticmetastasesstatus AT hongliangzou retrospectivecomparativesurvivalanalysisofablationplussystemictherapyversussystemictherapyaloneforbreastcancerlivermetastasesstratifiedbyextrahepaticmetastasesstatus AT xuanluo retrospectivecomparativesurvivalanalysisofablationplussystemictherapyversussystemictherapyaloneforbreastcancerlivermetastasesstratifiedbyextrahepaticmetastasesstatus AT xuweichen retrospectivecomparativesurvivalanalysisofablationplussystemictherapyversussystemictherapyaloneforbreastcancerlivermetastasesstratifiedbyextrahepaticmetastasesstatus AT weilinghuang retrospectivecomparativesurvivalanalysisofablationplussystemictherapyversussystemictherapyaloneforbreastcancerlivermetastasesstratifiedbyextrahepaticmetastasesstatus AT chaozhang retrospectivecomparativesurvivalanalysisofablationplussystemictherapyversussystemictherapyaloneforbreastcancerlivermetastasesstratifiedbyextrahepaticmetastasesstatus AT geren retrospectivecomparativesurvivalanalysisofablationplussystemictherapyversussystemictherapyaloneforbreastcancerlivermetastasesstratifiedbyextrahepaticmetastasesstatus AT jinhuahuang retrospectivecomparativesurvivalanalysisofablationplussystemictherapyversussystemictherapyaloneforbreastcancerlivermetastasesstratifiedbyextrahepaticmetastasesstatus AT xuehan retrospectivecomparativesurvivalanalysisofablationplussystemictherapyversussystemictherapyaloneforbreastcancerlivermetastasesstratifiedbyextrahepaticmetastasesstatus AT yiquanjiang retrospectivecomparativesurvivalanalysisofablationplussystemictherapyversussystemictherapyaloneforbreastcancerlivermetastasesstratifiedbyextrahepaticmetastasesstatus |